Edinburgh-based biotech pioneer behind technology described as the “holy grail for emerging gene therapies” has been given a £3 million funding injection.
Concinnity Genetics - co-founded by Jessica Birt and Matthew Dale - has developed novel control mechanisms using a cutting-edge artificial intelligence (AI) platform and its synthetic biology expertise.